PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

First Patient in Singapore Treated with TheraSphere® Radioembolization Therapy - BTG plc announced the treatment of the first patient in Singapore with TheraSphere® specifically engineered to deliver powerful doses of radiation to the tumour while minimising exposure to normal tissue
First Patient in Singapore Treated with TheraSphere® Radioembolization Therapy

 

NewswireToday - /newswire/ - London, United Kingdom, 2015/06/11 - BTG plc announced the treatment of the first patient in Singapore with TheraSphere® specifically engineered to deliver powerful doses of radiation to the tumour while minimising exposure to normal tissue. LSE: BTG

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BTG plc, the specialist healthcare company, today announced the treatment of the first patient in Singapore with TheraSphere®, a treatment for primary liver cancer and metastatic colorectal cancer, specifically engineered to deliver powerful doses of radiation to the tumour while minimising exposure to normal tissue.

Associate Professor Stephen Chang, Liver Tumour Group Lead and Senior Consultant, National University Cancer Institute, Singapore and National University Hospital, said: “Liver cancer is a deadly disease that impacts hundreds of people in Singapore each year and has a high mortality rate. This newly available therapy aims to destroy tumour cells, while maintaining the patient’s quality of life.”

TheraSphere® is a targeted therapy that consists of millions of glass microspheres containing radioactive yttrium-90. The microspheres are about 20-30 micrometers in diameter about a third of the width of a human hair. They are delivered directly to liver tumours through the hepatic artery using a catheter. The glass microspheres flow directly into the liver tumour via its blood vessels and become permanently lodged there. Because the procedure delivers the treatment directly to the liver tumour, the radiation destroys the tumour cells with minimal impact to the surrounding healthy liver tissue. The radioactive microspheres continue to deliver radiation to the tumour over the course of several weeks after treatment. TheraSphere® can also be used as a bridge to surgical removal of diseased tissue or transplantation in these patients.

James Glasgow, General Manager, BTG Asia, said: “Today’s announcement is an important milestone for this therapy and for BTG’s geographic expansion in Asia. Singapore is the second Asian market where we have launched TheraSphere® and we’re proud to be providing a new treatment option for patients with liver cancer.”

In Singapore TheraSphere® is approved for both hepatocellular carcinoma (HCC), also known as primary liver cancer, and metastatic liver cancer or cancer that has spread to the liver from another point of origin. Distributed in Singapore by Transmedic PTE Ltd., TheraSphere® is also commercially available in Hong Kong. Over 18,000 patients worldwide have been treated with TheraSphere®.

The National University Hospital in Singapore, and more than 20 hospitals across Asia, will also be participating in three international Phase III clinical trials of TheraSphere®.

• The EPOCH trial, evaluating TheraSphere® in patients with metastatic colorectal carcinoma (mCRC) of the liver who have failed first-line chemotherapy.
• The STOP-HCC trial, evaluating TheraSphere® in the treatment of patients with unresectable hepatocellular carcinoma.
• The YES-P trial, evaluating TheraSphere® versus the standard of care (sorafenib) for the treatment of advanced hepatocellular carcinoma with portal vein thrombosis.

About Liver Cancer
The Asia-Pacific region accounts for up to 80% of the world’s total liver cancer cases.[ii] Liver cancer is the 4th most common cancer among men in Singapore, accounting for 7.5% of the male incidence of cancers and has the 3rd highest mortality rate.

Primary liver cancer occurs when liver cells become abnormal and grow uncontrollably, forming a tumour. The most common form of primary liver cancer is called hepatocellular carcinoma (HCC). It is one of the most common forms of cancer worldwide, with an estimated one million new cases diagnosed each year. Long term infection with the hepatitis B or hepatitis C virus, which are more prevalent in Asian countries, are a common cause of cirrhosis and liver cancer.

The liver, which continuously filters blood circulating through the body, is also susceptible to “secondary” cancers, caused when tumours in other organs such as the colon, rectum, breast, head or neck have spread to the liver. These tumours are also known as liver metastases. The liver is the most common site of metastasis in patients with colorectal cancer.

Contacts:
Andy Burrows, Vice President, Corporate and Investor Relations
P: +44(0)20 7575 1741 / M: +44(0)79 9053 0605

Stuart Hunt, Investor Relations Manager
P: +44(0)20 7575 1582

FTI Consulting - Ben Atwell
P: +44(0)20 7831 3113

About BTG
BTG (btgplc.com) is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of liver tumours, severe blood clots, varicose veins and advanced emphysema, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today’s most complex healthcare challenges.

i Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 2011;79(1):163 71.
ii Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010;52(5):1741 9.
iii Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 2014;60(1):192 201.
iv Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013;57(5):1826 37.
[ii] Comprehensive Liver Cancer Clinic (CLCC) at the National Cancer Center Singapore
v Singapore Cancer Registry, Interim Annual Registry Report, Trends in Cancer Incidence in Singapore 2009-2013
vi Wong C, Goh K. Chronic hepatitis B infection and liver cancer. Biomedical Imaging and Intervention Journal. 2006;2(3):e7. doi:10.2349/biij.2.3.e7.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


First Patient in Singapore Treated with TheraSphere® Radioembolization Therapy

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

BTG plc | TheraSphere®
Publisher Contact: Chris Sampson - BTGplc.com 
+44(0)20 7575 1595 chris.sampson[.]btgplc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biocompatibles UK Ltd / BTG Plc / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)